Amendments to the Claims

The following listing replaces all prior versions and listings of claims in the application.

Listing of Claims

- 1. (Currently Amended) A <u>An immunogenic</u> complex comprising a negatively-charged organic complex and a charged antigen, where (A) said organic complex <u>comprises a saponin and a sterol</u> and (B) <u>said organic complex and</u> antigen are electrostatically associated and (B) <u>said complex generates a cytotoxic CTL response when administered to a mammal</u>.
- 2. (Currently Amended) The <u>immunogenic</u> complex according to claim 1 wherein said antigen is positively charged <u>comprises a positive charge</u>.
- 3. (Currently Amended) The <u>immunogenic</u> complex according to claim 2 wherein said antigen is a protein or <u>derivative or equivalent thereof</u> comprises a peptide region.
 - 4. Canceled.
 - 5. Canceled.
- 6. (Currently Amended) The <u>immunogenic</u> complex according to claim 5 1 wherein said <u>adjuvant organic complex</u> is a naturally negatively charged <u>adjuvant complex</u> which has been modified to increase the degree of its negative charge.
- 7. (Currently Amended) The <u>immunogenic</u> complex according to claim 5 2 or 3 wherein said protein is a naturally positively charged protein which antigen has been modified to increase the degree of its positive charge.
- 8. (Currently Amended) The <u>immunogenic</u> complex according to claim 5 3 wherein said <u>adjuvant organic complex</u> is a naturally negatively charged <u>adjuvant complex</u> which has been modified to increase the degree of its negative charge and said <u>protein peptide</u> is a naturally positively charged <u>protein antigen</u> which has been modified to increase the degree of its positive charge.
 - 9. canceled.
 - 10. canceled.



Serial No.: 09/506,011

11. canceled.

- 12. (Currently Amended) The <u>immunogenic</u> complex according to claim 5 <u>1</u> wherein said adjuvant is comprises a phospholipid.
- 13. (Currently Amended) The <u>immunogenic</u> complex according to claim 12 wherein said phospholipid is a phosphoglyceride.
- 14. (Currently Amended) The <u>immunogenic</u> complex according to claim 13 wherein the phosphoglyceride is selected from the group consisting of phosphatidyl inositol, phosphatidyl glycerol, phosphatidic acid and cardiolipin.
- 15. (Currently Amended) The <u>immunogenic</u> complex according to claim 12 wherein said phospholipid is lipid A.
- 16. (Currently Amended) The <u>immunogenic</u> complex according to claim 15 wherein the lipid A is selected from the group consisting of diphosphoryl lipid A and monophosphoryl lipid A.
- 17. (Currently Amended) The <u>immunogenic</u> complex according to claim 1 wherein said complex induces a cytotoxic T-lymphocyte response <u>when administered to a mammal</u>.

18-52. canceled.

53. (New) An immunogenic complex comprising a negatively-charged organic complex and a charged antigen, where (A) said organic complex and said antigen are electrostatically associated and (B) said complex generates a cytotoxic CTL response when administered to a mammal.